Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Hyperkalemia is a commonly encountered clinical problem and has been reported in up to 10% of hospitalized patients, with 10% to 38% of those episodes associated with medications that block the renin-angiotensin-aldosterone system (RAAS).1 Mortality has been shown to be increased in patients with hyperkalemia even after accounting for other comorbidities.2
Dixon BS. Zirconium Cyclosilicate for Treatment of Hyperkalemia. JAMA. 2014;312(21):2217–2218. doi:10.1001/jama.2014.15736
Customize your JAMA Network experience by selecting one or more topics from the list below.